title: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.
abstract: BACKGROUND
  Mycophenolate mofetil (MMF) is a new immunosuppressant with pharmacodynamic properties comparable to azathioprine. Recent reports found MMF to be effective in inflammatory bowel disease (IBD).
  
  
  METHODS
  An open-label prospective and uncontrolled multicentre 6 month trial of MMF in combination with steroids was conducted in 24 chronic active IBD patients. A daily steroid demand of >/= 10 mg prednisone in the preceding 2 months and a Crohn's disease activity index (CDAI) > 150, or moderate to severe activity according to Truelove, served as criteria for chronic activity. The treatment consisted of a steroid pulse and tapering protocol in combination with MMF 2 g/day. A prednisone dose of 5 mg/day was maintained during months 4-6. The primary end-point was induction and maintenance of remission.
  
  
  RESULTS
  Only 10 of 24 patients had achieved remission after 3 months. All but one Crohn's disease patient had relapsed by the end of the study at 6 months. Depression and migraine necessitated drug withdrawal in two patients.
  
  
  CONCLUSIONS
  In conclusion, MMF 2 g/day was unable to induce and maintain remission for a period of 6 months in 23 of 24 chronic active IBD patients. Further controlled investigations are required in view of recent conflicting reports.
authors.affiliation: Department of Internal Medicine I, Division of Gastroenterology, University of Lübeck, Lübeck, Germany. klaus.fellermann@medinf-mu.luebeck.de
authors.forename: K
authors.initials: K
authors.lastname: Fellermann
authors.forename: M
authors.initials: M
authors.lastname: Steffen
authors.forename: J
authors.initials: J
authors.lastname: Stein
authors.forename: A
authors.initials: A
authors.lastname: Raedler
authors.forename: J
authors.initials: J
authors.lastname: Hämling
authors.forename: D
authors.initials: D
authors.lastname: Ludwig
authors.forename: K
authors.initials: K
authors.lastname: Loeschke
authors.forename: E F
authors.initials: EF
authors.lastname: Stange
mesh_terms: D000328:Adult; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D011241:Prednisone